Comparison Study of SIBP's MMR Vaccine Versus GSK MMR Vaccine in Children Aged 9-11 Months

Inclusion Criteria: * Healthy male and female child as established by medical history and clinical examination at enrollment. * Age: 9-11 months (inclusive) at the time of enrollment * Parent's/legally acceptable representative's (LAR) ability to read and willingness to provide written informed consent as per the ethical and regulatory requirements of the site. * Parent confirms intention to stay in the study area for the study duration, bring their child in for the required study visits or to accept a home visit by the study staff. Exclusion Criteria: * Presence of fever (defined as axillary temperature ≥ 37.5°C) (temporary exclusion until recovery) * Acute disease of moderate to severe intensity at the time of enrollment (temporary exclusion until recovery) * Use of antipyretics within the last 72 hours prior to enrolment (temporary exclusion until recovery) * Prior (within 6 months) or concurrent participation in another interventional clinical trial during the study * Presence of severe malnutrition (weight-for-height z-score \< -3SD median) * Positive test for any of the following: HIV, hepatitis B, hepatitis C and syphilis * Presence of any systemic disorder (cardiovascular, pulmonary, hepatic, renal, gastrointestinal, hematological (including severe anemia), endocrine, immunological, dermatological, neurological, cancer, or autoimmune disease) as determined by medical history and / or physical examination which would compromise the participant's health or is likely to result in nonconformance to the protocol. * Known or suspected impairment of immunological function based on medical history and physical examination. * Prior receipt or intent to receive measles, mumps, rubella, or yellow fever-containing vaccine during the study vaccination and follow up period up to Day 85 outside the study center. * Receipt of any vaccine (except OPV and inactivated influenza) within 4 weeks of the day of study vaccination or intent to receive any within 6 weeks after study vaccination. * Receipt of immunoglobulin therapy and / or blood products in the past 9 months or planned administration during the study period * Receipt of any immune-modifying or immunosuppressant drugs prior to the first study vaccine dose or planned use during the study. A chronic oral or parenteral use (defined as more than 14 days) of high dose corticosteroids (defined as ≥2 mg/kg of body weight or ≥20 mg/day of prednisone or equivalent for persons who weigh \>10 kg) will be exclusionary for the study. Children on inhaled or topical steroids may be permitted to participate in the study. * Evidence of a clinically significant major congenital anomaly or genetic defect as judged by the investigator. * Any known or suspected bleeding disorder in the participant that would pose a risk to venipuncture or intramuscular injection. * History of any neurologic disorders including encephalopathy, epilepsy, and other progressive neurological diseases * A known or suspected sensitivity or allergy to any components of the investigational product including egg, chicken protein and the antibiotic gentamycin. * History of severe allergic reaction with generalized urticaria, angioedema, or anaphylaxis. * Any medical condition in the parent/LAR or child which, in the judgment of the Investigator, would interfere with or serves as a contraindication to protocol adherence or a participant's parent(s)'/LAR's ability to give informed consent.